Breaking News

On the rift between BIO and China's WuXi 

April 18, 2024
Biotech Correspondent

Morning! Today, some Parkinson's data from Cerevel that makes AbbVie's planned $8.7 billion acquisition look good, we see a couple of startups launch with big venture bucks, and explore why WuXi and BIO are no longer copacetic.

 

The need-to-know this morning


Parkinson's

Cerevel drug improves motor function in Parkinson's

Tavapadon, an experimental Parkinson's drug developed by Cerevel Therapeutics, improved motor symptom control in patients in a late-stage trial. When taken with levodopa, a standard treatment for the neurodegenerative disease, the patients given tavapadon experienced an improvement of 1.7 hours of "on time" without involuntary movement. The patients in the placebo arm were also given levodopa, but only had 0.6 hours of improved "on time," which is a period during which patients can move and function well.

AbbVie last year said it would acquire Cerevel for $8.7 billion, though it was largely focused on another drug in its pipeline — emraclidine — which is being studied in schizophrenia and psychosis linked to Alzheimer's and Parkinson's. These positive results are, in a sense, an added bonus for AbbVie's M&A strategy.

Read more.


obesity

Obesity-centric Metsera launching with $290 million 

Metsera, a new startup that's already licensed a trove of obesity-centric drug candidates, is emerging from stealth with an impressive $290 million in seed and Series A financing. With backing from ARCH Venture Partners and others, Metsera has licensed several drug candidates from South Korean biotech D&D Pharmatech. It also acquired a small company called Zihipp that held a library of about 20,000 gut hormone peptides.

Metsera's plush pipeline includes a GLP-1 targeting drug, and another focused on amylin, a hormone that's excreted along with insulin by pancreatic cells. It's developing a "triple G" compound that targets three hormone receptors: GLP-1, GIP, and glucagon. It's also creating a way to make its peptide therapies into pills, STAT's Allison DeAngelis writes.

"We feel that the market is at a point where the proof of principle is amazing. … Now the question is, how do you not invent, but innovate? How do you make the market work by providing [for] people with different needs?" CEO Clive Meanwell told STAT.

Read more.



china

Why the relationship between BIO and WuXi went sour

Not so long ago, China's WuXi Biologics and BIO enjoyed a certain camaraderie: The CEOs of both groups shook hands and grinned in a photo posted on LinkedIn. But just a few months later, BIO and WuXi AppTec, a sister company, ended their relationship — and John Crowley, CEO of the biotechnology trade group, expressed his support for legislation that would prevent the U.S. biotech sector from collaborating with the Chinese company.

This sudden change illustrates how the biotech industry is struggling to handle quickly changing issues of national security, STAT's John Wilkerson writes. The growing tension makes it hard for industry stateside to talk with Congress about how to effectively manage relationships with Chinese companies.

This is a test for Crowley, who only recently took the helm at BIO and doesn't have a background in politics. Now, one of his main missions is a delicate one — navigating the souring relations between the U.S. and China in biotech.

Read more.


artificial intelligence

An AI tool to predict metastatic cancer's origins

It's hard to pin down the origin of a cancer's metastasis, but a new AI tool is outperforming pathologists in finding a malignancy's source, Nature writes. The deep-learning algorithm, developed by researchers at the Tianjin Medical University in China, was trained on some 30,000 images of cells found in abdominal or lung fluid from 21,000 people whose tumor of origin was known. They then tested their model on 27,000 images, and found that it had an 83% chance of accurately predicting the cancer's source. And there was a 99% chance that the tool's guess was in its top three predictions. When studying 500 images, the AI tool was better than human pathologists in guessing a tumor's origin.

Although this is just proof-of-concept, a model like this could help reduce the number of tests a cancer patient needs to take. The origin of about 5% of all metastatic tumors can't be identified, which makes them harder to treat: A cancer cell that originated in the breast might still resemble a breast cancer cell, even if it's elsewhere in the body. Understanding the origins can help physicians tailor therapies.


 

cancer vaccines

Corner Therapeutics launches with $54 million

With a $54 million Series A in hand, a startup called Corner Therapeutics is launching with plans to develop vaccines for cancer, influenza, and perhaps HIV. The company was first conceived in 2019 by two Harvard-affiliated scientists and Andrew Bellinger, the current chief scientific officer of the gene editing company Verve Therapeutics. It's also being led by Spark Therapeutics co-founder and former Children's Hospital of Philadelphia CEO Steven Altschuler.

Corner's approach centers on hyper-activating the subcutaneous dendritic cells, STAT's Allison DeAngelis writes, which work as beacons at various points in the body to signal when the immune system needs to be activated. Corner hopes to dial up the dendritic cell response in order to rev up the immune system.

"That really was the major innovation that started the company: our ability to harness the power of hyperactive dendritic cells, so that we can not just provide short-term immune protection, but rather durable immunity," scientific co-founder Jonathan Kagan told STAT. "The difference there is really the difference between five-year survival rate discussions with cancer versus cures."

Read more.


The newsletter yesterday incorrectly stated that the FDA has already agreed to expedite review of Zepbound in obstructive sleep apnea. It should have said that the FDA has granted fast-track designation to Zepbound in sleep apnea, a signal that the agency considers the disease to be serious enough to potentially warrant an expedited review.

The newsletter also incorrectly described Cullinan Therapeutics as a cell therapy company; it is an oncology company. Cullinan is developing a CD19xCD3 T cell engager called CLN-978 to treat systemic lupus erythematous.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

More reads

  • Pfizer's academic-partnered R&D unit is scrapped as part of cost-cutting measures, FierceBiotech

  • Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA says, Reuters

  • GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up, Endpoints


Thanks for reading! Until tomorrow,


Enjoying The Readout? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments